Doug Onsi
Chief Executive Officer chez LEAP THERAPEUTICS, INC.
Fortune : 195 901 $ au 31/03/2024
Profil
Doug E.
Onsi is currently the President, CEO, CFO, Secretary & Treasurer at Leap Therapeutics, Inc. He is also a Director at Potentia Pharmaceuticals, Inc., Adheron Therapeutics, Inc., Healthcare Pharmaceuticals, Inc. (Utah), and Vaxxas Pty Ltd.
Additionally, he holds the position of Managing Director at HealthCare Ventures LLC, Healthcare Ventures VII LP, and Healthcare Partners IX LLC.
He is also a Managing Director at Healthcare Strategic Partners, LLC.
In the past, Mr. Onsi served as the President, Chief Executive Officer & Director at TetraLogic Research & Development Corp.
from 2013 to 2014.
He was also a Director at Oriel Therapeutics, Inc., Sequoia Pharmaceuticals, Inc., Sierra Neuropharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Apofore Corp., Tensha Therapeutics, Inc., Anexon, Inc., and LeukoSite, Inc. Furthermore, he held the position of Vice President-Campath Product Operations at Genzyme Corp.
from 2007 to 2007 and Chief Financial Officer at Tolerx, Inc. from 2004 to 2004.
He also worked as an Attorney at Bingham Dana LLP and was a Member of the Cornell University Council.
Mr. Onsi completed his undergraduate degree at Cornell University in 1990 and obtained his graduate degree from The University of Michigan Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LEAP THERAPEUTICS, INC.
0,29% | 29/01/2024 | 73 647 ( 0,29% ) | 195 901 $ | 31/03/2024 |
Postes actifs de Doug Onsi
| Sociétés | Poste | Début |
|---|---|---|
| LEAP THERAPEUTICS, INC. | Chief Executive Officer | 01/04/2020 |
HealthCare Ventures LLC
 HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/08/2007 |
Healthcare Ventures VII LP
 Healthcare Ventures VII LP Investment ManagersFinance HealthCare Ventures VII LP seeks investment opportunities in life science companies located in the US with an annual revenues ranging from $50 - $100 million. The fund targets companies operating in the fields of cancer therapy, infectious diseases, cardiovascular diseases, central nervous system disorders, immunotherapy, novel manufacturing technologies and novel lab scale instruments & reagents. It provides financing in the form of equity and debt convertible to equity for early and later stage capital requirements with an investment size of $1,000,000 - $20,000,000. It also makes investments in both private and public companies. | Corporate Officer/Principal | - |
| Healthcare Partners IX LLC | Corporate Officer/Principal | - |
| Healthcare Pharmaceuticals, Inc. (Utah) | Director/Board Member | 01/01/2010 |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Director/Board Member | 01/01/2008 |
Vaxxas Pty Ltd.
 Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Director/Board Member | 01/01/2011 |
Potentia Pharmaceuticals, Inc.
 Potentia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Potentia Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel therapeutics and drug delivery technologies to address chronic inflammatory diseases. The company was founded by Cedric Francois, David Darst, Alec Machiels and Pascal Deschatelets in 2001 and is headquartered in Crestwood, KY. | Director/Board Member | 01/01/2008 |
Healthcare Strategic Partners, LLC
 Healthcare Strategic Partners, LLC Medical/Nursing ServicesHealth Services Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services. | Corporate Officer/Principal | - |
Anciens postes connus de Doug Onsi
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Doug Onsi
| Cornell University | Undergraduate Degree |
| The University of Michigan Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| LEAP THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 20 |
|---|---|
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Oriel Therapeutics, Inc.
 Oriel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oriel Therapeutics, Inc. develops inhaled drug delivery systems for respiratory diseases and diagnostics. It is a respiratory drug delivery and development company serving the pharmaceutical, biotechnology and diagnostic industries in the development and commercialization of innovative pre-metered unit and multi-dose dry powder delivery systems for medicines for asthma and chronic obstructive pulmonary disease. The company was founded by Paul J. Atkins, Timothy M. Crowder, Richard Fuller and Anthony J. Hickey in 2002 and is headquartered in Durham, NC. | Health Technology |
Sequoia Pharmaceuticals, Inc.
 Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Potentia Pharmaceuticals, Inc.
Potentia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Potentia Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel therapeutics and drug delivery technologies to address chronic inflammatory diseases. The company was founded by Cedric Francois, David Darst, Alec Machiels and Pascal Deschatelets in 2001 and is headquartered in Crestwood, KY. | Health Technology |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Health Technology |
Sierra Neuropharmaceuticals, Inc.
 Sierra Neuropharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sierra Neuropharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of centrally-administered, small molecule therapeutics for the treatment of severe central nervous systems diseases refractory to oral medications. These include epilepsy, schizophrenia, bipolar disorder, anxiety disorders and major depression. The company uses a proprietary drug development process to reformulate pharmaceuticals for direct delivery to the brain via standard implantable pumps. The company was founded in 2005 and is headquartered in Aurora, CO. | Health Technology |
Apofore Corp.
 Apofore Corp. Pharmaceuticals: MajorHealth Technology Apofore Corp. developed novel therapeutics for diabetes. The company was headquartered in Cambridge, MA. | Health Technology |
Tensha Therapeutics, Inc.
 Tensha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tensha Therapeutics, Inc. develops small molecule bromodomain inhibitors. The firm’s product is used to treat cancer and other serious disorders. The company was founded by James Bradner in 2011 and is headquartered in Cambridge, MA. | Health Technology |
HealthCare Ventures LLC
HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Finance |
| Bingham Dana LLP | Commercial Services |
Healthcare Ventures VII LP
Healthcare Ventures VII LP Investment ManagersFinance HealthCare Ventures VII LP seeks investment opportunities in life science companies located in the US with an annual revenues ranging from $50 - $100 million. The fund targets companies operating in the fields of cancer therapy, infectious diseases, cardiovascular diseases, central nervous system disorders, immunotherapy, novel manufacturing technologies and novel lab scale instruments & reagents. It provides financing in the form of equity and debt convertible to equity for early and later stage capital requirements with an investment size of $1,000,000 - $20,000,000. It also makes investments in both private and public companies. | Finance |
Anexon, Inc.
 Anexon, Inc. Pharmaceuticals: MajorHealth Technology Anexon, Inc. develops therapeutics for cardiovascular diseases. The firm develops an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was founded in 2006 by Robert D. Simari and is headquartered in Cambridge, MA. | Health Technology |
| Healthcare Pharmaceuticals, Inc. (Utah) | |
TetraLogic Research & Development Corp.
 TetraLogic Research & Development Corp. BiotechnologyHealth Technology TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Vaxxas Pty Ltd.
Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Health Technology |
| Cornell University Council | |
Healthcare Strategic Partners, LLC
Healthcare Strategic Partners, LLC Medical/Nursing ServicesHealth Services Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services. | Health Services |
| Healthcare Partners IX LLC |
